Tag archive

JNJ

Some Thoughts On JNJ and Abbott Labs

in Stock Analysis by

It seems that 2007 should be a brighter year for Johnson & Johnson (NYSE JNJ).  In 2006 the company faced major drug expirations which dampened revenue growth. I really like the Pfizer’s (PFE) consumer business acquisition. Despite having a fairly good product line, Pfizer Inc was a pharmaceutical company that happened to have consumer products which came…

Keep Reading

Great Job Bob!

in Stock Analysis by

Herb Greenberg wrote a wonderful column and said something I’ve wanted to say for a long time, that blaming Bob Nardelli for the lackluster performance of Home Depot’s (HD) stock is just plain silly. Since Nardeli took over Home Depot in 2000, Home Depot’s earnings have grown at an amazing clip of 20% a year, revenues over 15%, net margins have increased…

Keep Reading

Go to Top